Secondary analyses also examined the extent to which the brief intervention could facilitate help-seeking in the form of either speaking to a physician or nurse about smoking or calling a local smoking quitline. Second, this study sought to evaluate a highly modified low-intensity selleckchem EPZ-5676 version of CM (hereafter referred to as CM-Lite) designed to be maximally replicable in the community��in part through the use of technology to facilitate implementation. We hypothesized that the CM-Lite intervention would result in decreased smoking when compared with time control plus TAU but did not predict greater efficacy than the brief intervention because of the substantial differences (e.g., participant initiated, less frequent sessions, lower incentive value) between CM-Lite and traditional CM.

Third, we wished to examine the extent to which the combination of CD-5As and CM-Lite might lead to enhanced effects relative to each intervention alone. To meet these goals, we recruited 110 women reporting smoking during pregnancy from one of four prenatal care clinics and randomly assigned them to either a single-session computer-delivered brief intervention (CD-5As), an invitation to participate in CM-Lite, a combined condition (CD-5As plus an invitation to participate in CM-Lite), or a brief nonsmoking-related computer session (to control for time using the computer) plus TAU. Data were collected at baseline and 10-week follow-up. Methods Participants Participants were 110 pregnant women recruited from one of four prenatal care clinics in Detroit, MI.

Inclusion criteria included being age 18 years or older, being no further than 27 weeks into gestation, and reporting smoking in the past week (while pregnant); women were excluded if they were unable to understand spoken English. The sample size of 110 was determined primarily by funding and time constraints in this preliminary trial, which was not intended to be fully powered. The Wayne State University��s Institutional Review Board approved all procedures used in this study. Design and Procedures The present study was a factorial randomized clinical trial (registered with Clinicaltrials.gov, number NCT01028131, protocol available from first author) in which research staff were blind to each participant��s brief intervention status but were aware of CM-Lite status GSK-3 (research staff conducted all CM-Lite testing and reinforcement procedures for this study). Participants were reevaluated approximately 10 weeks after the initial baseline/randomization/intervention session by research assistants who were blind to that participant��s brief intervention status. Women were approached while in the clinic waiting area and completed eligibility screening either by computer or paper-and-pencil self-report.